SELDI
Vermillion, Bio-Rad Settle Claims Stemming from Sale of Proteomics Technology
NEW YORK (GenomeWeb News) – Vermillion today announced that all four non-contingent contract claims with Bio-Rad Laboratories stemming from Vermillion's sale of its proteomics business
ProteoMonitor spoke to Cristobal Belda-Iniesta, head of the Biomarkers and Experimental Therapeutics for Cancer Group at Madrid's University Hospital La Paz, about his work applying proteomics to guide cancer therapy.
The patent's claims cover biomarker combinations for the diagnosis and management of Alzheimer's disease and their measurement by methods including mass spectrometry and immunoassay.
The system, called Lucid Proteomics, combining Bio-Rad's SELDI-based array technology with Bruker's ultrafleXtreme MALDI-TOF/TOF instrument, is expected to hit the market in late summer or early fall, and is the first fruit of a co-marketing and co-development collaboration between the two firms announced a month ago.
The company remains in business and continues work to get FDA approval for its ovarian tumor triage diagnostic. In its filing, the company said it had assets of about $7.2 million and liabilities of approximately $32 million as of Sept. 30, 2008.
Mar 26, 2009